China's I-Mab gets boost from AbbVie to develop cancer therapy - STAT

China's I-Mab gets boost from AbbVie to develop cancer therapy - STAT

STAT Plus: ‘The race is on’: China’s I-Mab gets boost from AbbVie to develop a new cancer immunotherapy

By JONATHAN CHAN

RUBY WALLAU FOR STAT

Shanghai-based I-Mab has signed a global collaboration deal with U.S. drug maker AbbVie to develop lemzoparlimab, I-Mab’s homegrown cancer immunotherapy.

READ MORE